Publication | Closed Access

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

Metastatic Breast CancerBreast OncologyCancer ImmunosurveillanceImmunologyTumor ImmunityTherapeutic VaccineBreast CancerImmunotherapeuticsImmunotherapyMedicineRadiation Oncology